🇺🇸 FDA
Patent

US 11376324

Sting activating nanovaccine for immunotherapy

granted A61KA61K2039/55555A61K2239/31

Quick answer

US patent 11376324 (Sting activating nanovaccine for immunotherapy) held by The Board of Regents of the University of Texas System expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K2039/55555, A61K2239/31, A61K2239/38, A61K39/0011